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consistent application of low air-
way pressure and low tidal vol-
ume ventilation (a lung-protective 
strategy). Some trials, the largest 
of which was the lower tidal vol-
ume trial conducted by the ARDS 
Clinical Trials Network,3 revealed 
that reducing tidal volume from 
a typical traditional size of 12 ml 
per kilogram of actual body 
weight to 6 ml per kilogram of 
predicted body weight reduced mor-
tality by 9%.3 The remainder of 
the reduction in overall mortality 
in modern ICUs has not been 
clearly explained, but it appears 
to be attributable to better train-
ing of physicians, nurses, respi-
ratory therapy staff, and others 
involved in the routine care of 
patients with ARDS. Improved 
alarm systems, ventilator equip-
ment, and radiologic and labora-
tory evaluation — the availability 
of magnetic resonance imaging 
and computed tomography, for 
example, as well as point-of-care 
testing with rapid return of re-
sults — have undoubtedly also 
contributed.
Though the vast improvement 
in ICU and hospital mortality 
from ARDS is heartening, the 
poor subsequent condition of the 
growing number of survivors is 
showing us that much more needs 
to be done. Full recovery in pa-
tients who have been hospital-
ized with ARDS happens very 
slowly, if at all. At 1 year after 
discharge, vital capacity and 6-min-
ute walk distance remain signifi-
cantly reduced from patients’ pre-
ARDS status. Furthermore, less 
than half of such patients have 
been able to return to work.4 Per-
haps most worrisome, as many 
as 50% of patients who have re-
ceived mechanical ventilation in 
an ICU — commonly but not al-
ways because of ARDS — have 
cognitive impairment as long as 
a year after hospital discharge.5
We have come a long way 
since the middle of the last cen-
tury with regard to recognition, 
evaluation, treatment, and long-
term follow-up of patients with 
ARDS. Related mortality has fall-
en so far that it may be reaching 
a floor rate dictated more by the 
underlying diseases associated 
with ARDS — such as sepsis, 
severe trauma, or pancreatitis — 
than by either the syndrome itself 
or other associated organ dys-
function. Fortunately, such prog-
ress allows us to turn a much 
larger portion of our research 
and clinical attention to the rap-
idly growing population of ICU 
survivors.
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We have long known that metabolism must be tight-
ly controlled to support the needs 
of individual cells and tissues. 
Nutrient oxidation is necessary 
for the production of adenosine 
triphosphate (ATP), which supports 
energetically unfavorable processes 
in cells, and for the metabolic 
conversion of nutrients to build 
biomass in support of cell prolif-
eration. So it makes sense that 
disrupting metabolism can per-
turb normal development and that 
specific nutrient deficiencies can 
cause congenital anomalies. For 
example, folate deficiency delays 
neural tube closure, resulting in 
anencephaly or spina bifida, and 
fortification of cereal food prod-
ucts and folic acid supplementa-
tion in pregnant women have re-
duced the incidence of these birth 
defects.1 Thus, an understanding 
of the relationship between me-
tabolism and development can 
guide dietary interventions that 
reduce the risk of congenital de-
fects. In this issue of the Journal, 
Shi et al. (pages 544–552) report 
that a deficiency of nicotinamide 
adenine dinucleotide (NAD) causes 
congenital malformations, sug-
The New England Journal of Medicine 
Downloaded from nejm.org at MIT LIBRARIES on July 11, 2018. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
PERSPECTIVE
510
Metabolism and Congenital Malformations
n engl j med 377;6 nejm.org August 10, 2017
gesting that interventions to raise 
NAD levels during fetal and early 
postnatal development might fur-
ther reduce the incidence of con-
genital anomalies.
By sequencing the exomes or 
genomes of members of four un-
related families with offspring 
born with combinations of con-
genital defects that meet the cri-
teria for the so-called VACTERL 
association of vertebral, anal, car-
diac, tracheo-esophageal, renal, 
and limb anomalies, Shi et al. 
found loss-of-function mutations 
in two genes, each of which en-
codes an enzyme involved in the 
synthesis of NAD. The affected 
patients had loss-of-function mu-
tations in both copies of the 
gene encoding 3-hydroxyanthra-
nilic acid 3,4-dioxygenase (HAAO) 
or of the gene encoding kyn-
ureninase (KYNU) (see diagram). 
These mutations result in the ac-
cumulation of upstream interme-
diates in the kynurenine pathway 
and depletion of NAD.
Engineering the same enzyme 
deficiencies in mice resulted in 
birth defects similar to those 
found in humans, but only if they 
were combined with dietary inter-
ventions to reduce NAD levels. 
Deletion of Haao or Kynu in mice 
was sufficient to increase levels of 
upstream pathway intermediates 
but had no effect on development 
provided that sufficient NAD lev-
els were maintained through diet. 
Therefore, the authors could con-
clude that NAD depletion, rather 
Nicotinamide Adenine Dinucleotide Metabolism.
The diagram shows the pathway whereby nicotinamide adenine dinucleotide (NAD) is produced from the amino acid tryptophan by 
means of the kynurenine pathway enzymes kynureninase (KYNU) and 3-hydroxyanthranilic acid 3,4-dioxygenase (HAAO), along 
with the pathways involved in salvaging dietary precursors for NAD. Dietary precursors include niacin (nicotinic acid), nicotina-
mide riboside, nicotinamide mononucleotide, and nicotinamide. NAD is used in metabolism and in stress-response pathways 
involving poly(adenosine diphosphate–ribose) polymerases (PARPs) and sirtuin proteins.
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than the buildup of the upstream 
intermediates, was responsible for 
the congenital malformations.
NAD has a central role in cell 
metabolism. It is an electron car-
rier for redox reactions in cells 
(see diagram). Oxidized NAD 
(NAD+) can accept an electron 
pair as a cofactor in oxidation re-
actions, including those involved 
in glycolysis and the tricarboxylic 
acid cycle that are important for 
ATP production. NAD+ is also an 
electron acceptor in biosynthetic 
pathways, including pathways for 
the synthesis of purine and pyri-
midine nucleotides — fundamen-
tal building blocks of RNA and 
DNA. When NAD+ accepts elec-
trons, it is reduced to NADH. Be-
cause the pool of NAD+ is small 
relative to the flux through meta-
bolic pathways involving oxida-
tion reactions, NAD+ must be 
continually regenerated by trans-
ferring the electrons from NADH 
to another substrate, such as the 
terminal electron acceptors oxy-
gen or pyruvate. Thus, the con-
tinued shuttling of electrons be-
tween NADH and NAD+ is critical 
for many cellular processes, in-
cluding the generation of ATP 
and the synthesis of nucleotides. 
NAD+ can also be phosphory-
lated to generate NADP+ as a sec-
ond cofactor pool that when re-
duced to NADPH can provide 
electrons for reductive biosynthe-
sis and maintenance of a reduced 
intracellular redox state.
NAD+ is also a substrate for 
enzymes, such as the poly(adeno-
sine diphosphate[ADP]–ribose) 
polymerases (PARPs), that signal 
the presence of DNA damage and 
other types of cell stress. PARPs 
cleave nicotinamide from the ADP-
ribose portion of NAD+ and then 
catalyze the transfer of ADP- 
ribose to (and thereby activate) 
proteins involved in DNA repair, 
telomere maintenance, and other 
proteins that participate in cell-
stress responses.2 Another group 
of stress responders are members 
of the sirtuin family of proteins,3 
which use NAD+ as a cofactor and 
also release free nicotinamide.
The nicotinamide generated 
through the action of the PARPs 
and sirtuins can be salvaged to 
regenerate NAD. NAD can also 
be synthesized from the amino 
acid tryptophan through the kynu-
renine pathway or generated 
from dietary nicotinic acid (also 
known as niacin, part of the vita-
min B3 complex), as well as from 
dietary nicotinamide (also part 
of the vitamin B3 complex), nico-
tinamide riboside, or nicotinamide 
mononucleotide. Because these 
molecules permit NAD synthesis 
using enzymes that bypass the 
kynurenine pathway, supplemen-
tation of any of them in pregnant 
women or newborns with kynu-
renine pathway mutations should 
restore NAD levels. Furthermore, 
because supplementation is suf-
ficient to prevent congenital mal-
formations in mice with kynuren-
ine pathway mutations, ensuring 
adequate NAD levels during de-
velopment may reduce the risk of 
congenital malformations in hu-
mans and may also prevent cog-
nitive impairment in persons with 
VACTERL association.
How NAD deficiency causes 
congenital malformations is not 
known. Metabolism is coordinat-
ed with tissue differentiation to 
allow normal development.4 The 
fact that congenital defects simi-
lar to those found with NAD de-
ficiency are observed in persons 
with Fanconi anemia (caused by 
loss-of-function variants in the 
FANC genes) suggests that the 
two disorders have related under-
lying causes. Although it is also 
unclear how FANC variants cause 
congenital abnormalities, it is 
known that the FANC proteins 
guard against faulty DNA replica-
tion and repair, processes that are 
relevant to those of NAD metab-
olism: DNA-damage sensing and 
nucleotide production.
Regardless of how NAD de-
pletion leads to congenital mal-
formations (whether by compro-
mising the detection of DNA 
damage by PARP proteins, reduc-
ing the supply of nucleotides, or 
both), dietary supplementation 
with NAD precursors merits fur-
ther study. At high doses, niacin 
can cause flushing and gastroin-
testinal symptoms, but it has few 
side effects at lower doses. Nico-
tinamide mononucleotide, nicotin-
amide riboside, and nicotinamide 
itself are better tolerated than 
niacin and are generally consid-
ered to be safe as dietary supple-
ments, but the doses of NAD 
precursors required to reduce the 
risk of congenital malformations 
in humans are not known. Also 
unknown is the extent to which 
raising dietary levels of NAD 
would limit cognitive impairment 
in infants with congenital malfor-
mations.
Disclosure forms provided by the author 
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